A few weeks ago, Kaleidoscope hosted a panel discussion on effective leadership in biotech, at the CIC in Boston. We were lucky to be joined by some phenomenal leaders in the space, with expertise spanning successfully founding and selling companies, leading large teams, and investing at the cutting edge of the field. Below are three key takeaways, along with an audio recording of the event.
- Market timing matters. While being too late to the game is an obvious risk, so is being too early. It’s worth spending upfront time thinking through how your R&D roadmap does or doesn’t line up with the market’s readiness to adopt a new solution (market size, infrastructure, human psychology, etc.)
- Risk is inevitable — building a successful biotech is about finding ways to navigate that and take calculated risk. Make sure you understand your market, focus on developing your unique niche, and surround yourself with the right advisors or partners to fill any gaps you may have.
- People can make or break a project, partnership, or company. Take the time to get to know people and assess fit, before you start working with them. Being a good leader hinges on the ability to attract and vet top talent, give them focus, and unblock or empower them to do their best work.
- Ross Leimberg, Venture Partner at 82VS (Alloy Therapeutics)
- Lynne Frick, CEO at Cell X Technologies
- Dr. Tarek Fadel, Director Strategic Alliances & Partnerships at MIT, Founding Director of the MIT Convergence Scholars Program
- Dr. Evan Zhao, Co-founder & CEO at Revela, CSO at Oddity Labs
- Dr. Louis J. Kang, Co-founder at March Therapeutics, Partner at ACCELR8
- Julie O’Shaughnessy, Senior Director, Head of Digital Strategy and Business Operations at Resilience
Moderated by Dr. Mandana Manzari Honu, CSO at Kaleidoscope
If you’re interested in anything we write about or finding a way to work together, let us know!